Clinical Research Directory
Browse clinical research sites, groups, and studies.
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
Sponsor: University Health Network, Toronto
Summary
The proposed study is a phase II, single arm, open-label trial of MR-guided radiation therapy (RT) with risk stratified RT dose selection in patients with anal cancer. Based on previous data, a risk adaptive treatment approached is proposed in 4 groups: Low risk, standard risk, intermediate risk, and high risk. Human papillomavirus (HPV) DNA will be analyzed to identify novel biomarkers that predict chemoradiotherapy (CRT) response and toxicity.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2023-09-29
Completion Date
2028-09-01
Last Updated
2026-03-06
Healthy Volunteers
No
Conditions
Interventions
Radiotherapy - Low risk group
20 fractions completed in 4 weeks
Radiotherapy - Standard risk group
25 fractions completed in 5 weeks
Radiotherapy - Intermediate risk group
30 fractions completed in 6 weeks
Radiotherapy - High risk group
35 fractions completed in 7 weeks
Locations (4)
Allegheny Health Network
Pittsburgh, Pennsylvania, United States
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, United States
Austin Health
Heidelberg, Victoria, Australia
Princess Margaret Cancer Centre
Toronto, Ontario, Canada